candesartan has been researched along with Insulin Resistance in 35 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients." | 9.15 | Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. ( Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Salvadeo, SA; Santoro, T; Zoppi, A, 2011) |
| "In patients with hypertension and obesity showing insulin resistance, treatment with telmisartan significantly improved the hyperinsulin response to glucose loading." | 9.15 | Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). ( Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J, 2011) |
| "We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress." | 9.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| "We assessed the effects of candesartan in addition to angiotensin-converting enzyme (ACE) inhibitors on N-terminal pro-type natriuretic peptide (Nt-proBNP), systemic markers of inflammation and oxidative stress as well as on glucose regulation in patients with heart failure (HF)." | 9.12 | Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. ( Dabouz, F; De Denus, S; Ducharme, A; Gossard, D; Lavoie, J; Leblanc, MH; Lepage, S; Racine, N; Rouleau, JL; Touyz, R; White, M; Whittom, L, 2007) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 7.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "To investigate the effects of candesartan, an angiotension II type I receptor antagonist, in improvement of insulin resistance (IR) induced by high-fat diet and the possible mechanism thereof." | 7.74 | [Candesartan improves insulin resistance induced by high-fat diet in rats]. ( Chen, K; Dou, JT; Lu, JM; Ma, FL; Mu, YM; Pan, CY; Wang, XL; Wang, XM; Yan, WH; Yang, GQ, 2008) |
| "Candesartan (8 mg/d) was administered for 2 weeks to eight patients with essential hypertension to investigate the effect of an angiotensin II receptor antagonist on insulin sensitivity." | 7.70 | Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. ( Higashiura, K; Miyazaki, Y; Shimamoto, K; Ura, N, 1999) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 6.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "Candesartan treatment resulted in a significant decrease of systolic and diastolic blood pressures, LV mass index (LVMI), homeostasis model assessment (HOMA) index, and plasma brain natriuretic peptide (BNP)." | 6.71 | Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. ( Anan, F; Hara, M; Ooie, T; Saikawa, T; Takahashi, N; Yoshimatsu, H, 2004) |
| "Candesartan was orally administered to 12-week-old rats for 21 days, and age-matched rats without the agent were used as the respective controls." | 5.31 | Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. ( Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H, 2001) |
| "Of the pleiotropic effect related parameters investigated, urinary 8-isoprostane, fasting serum insulin and homeostasis model assessment of insulin resistance index were more suppressed after 4 weeks treatment with irbesartan than after candesartan and valsartan therapy, respectively." | 5.17 | Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers. ( Ando, H; Fujimura, A; Hosohata, K; Saito, T; Ushijima, K, 2013) |
| "The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients." | 5.15 | Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. ( Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Salvadeo, SA; Santoro, T; Zoppi, A, 2011) |
| "In patients with hypertension and obesity showing insulin resistance, treatment with telmisartan significantly improved the hyperinsulin response to glucose loading." | 5.15 | Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). ( Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J, 2011) |
| "In a previous study involving 18 hypertensive patients with type 2 diabetes mellitus, we found that replacement of valsartan and candesartan by telmisartan significantly improved insulin sensitivity and significantly increased serum adiponectin levels in the patients." | 5.14 | Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. ( Kondo, K; Nomura, Y; Oiso, Y; Ozaki, N; Sobajima, H, 2010) |
| "The aim of this study is to compare the effects of candesartan and olmesartan on insulin sensitivity-related parameters, before and after antihypertensive therapy." | 5.14 | Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2010) |
| "We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress." | 5.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| "Candesartan therapy significantly reduced inflammation and increased adiponectin levels and improved insulin sensitivity in hypertensive patients." | 5.12 | Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. ( Chung, WJ; Han, SH; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| "We evaluated whether the changes in the insulin sensitivity observed in hypertensive patients following treatment with an angiotensin II receptor blocker (candesartan) or calcium-channel antagonist (amlodipine) might be related to improvement of the endothelial function (END) and/or plasma level of high-sensitive C-reactive protein (CRP) following such treatment." | 5.12 | Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. ( Koji, Y; Motobe, K; Shiina, K; Tomiyama, H; Yamada, J; Yamashina, A; Yambe, M; Yoshida, M, 2007) |
| "We assessed the effects of candesartan in addition to angiotensin-converting enzyme (ACE) inhibitors on N-terminal pro-type natriuretic peptide (Nt-proBNP), systemic markers of inflammation and oxidative stress as well as on glucose regulation in patients with heart failure (HF)." | 5.12 | Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. ( Dabouz, F; De Denus, S; Ducharme, A; Gossard, D; Lavoie, J; Leblanc, MH; Lepage, S; Racine, N; Rouleau, JL; Touyz, R; White, M; Whittom, L, 2007) |
| "Prevention is an important goal in the treatment of hypertension." | 3.79 | Prehypertension: a possible target for antihypertensive medication. ( Julius, S; Nesbitt, SD, 2000) |
| " CD-fed SHR were simultaneously treated with either telmisartan (TEL; 8 mg/kg(body weight)· d) or candesartan (CAND; 10 mg/kg(body weight)· d) for 3 months because TEL, but not CAND, has been demonstrated to be a strong activator of PPARγ." | 3.78 | Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation. ( Heidbreder, M; Jöhren, O; Landolt, J; Müller-Fielitz, H; Raasch, W; Vogt, FM; Werth, S, 2012) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 3.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "To investigate the effects of candesartan, an angiotension II type I receptor antagonist, in improvement of insulin resistance (IR) induced by high-fat diet and the possible mechanism thereof." | 3.74 | [Candesartan improves insulin resistance induced by high-fat diet in rats]. ( Chen, K; Dou, JT; Lu, JM; Ma, FL; Mu, YM; Pan, CY; Wang, XL; Wang, XM; Yan, WH; Yang, GQ, 2008) |
| "Both TAK-536 and candesartan suppressed the increase in plasma glucose level in the OGTT without significant change in insulin concentration and improved insulin sensitivity." | 3.74 | TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. ( Chen, R; Horiuchi, M; Imura, Y; Iwai, M, 2007) |
| "Candesartan (8 mg/d) was administered for 2 weeks to eight patients with essential hypertension to investigate the effect of an angiotensin II receptor antagonist on insulin sensitivity." | 3.70 | Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. ( Higashiura, K; Miyazaki, Y; Shimamoto, K; Ura, N, 1999) |
| "In vivo, 56 patients with both type 2 diabetes and hypertension were enrolled and randomized to receive either telmisartan (40 mg) or candesartan (8 mg) for 3 months." | 2.73 | Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. ( Ano, N; Atsuda, K; Inoue, G; Irie, J; Kitaoka, A; Shiono, K; Toda, K; Yamada, S, 2008) |
| "Fenofibrate combined with candesartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy in hypertriglyceridemic hypertensive patients." | 2.72 | Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. ( Ahn, JY; Chung, WJ; Han, SH; Kim, JA; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 2.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "Candesartan treatment resulted in a significant decrease of systolic and diastolic blood pressures, LV mass index (LVMI), homeostasis model assessment (HOMA) index, and plasma brain natriuretic peptide (BNP)." | 2.71 | Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. ( Anan, F; Hara, M; Ooie, T; Saikawa, T; Takahashi, N; Yoshimatsu, H, 2004) |
| "Candesartan was orally administered to 12-week-old rats for 21 days, and age-matched rats without the agent were used as the respective controls." | 1.31 | Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. ( Daimon, M; Hirata, A; Igarashi, M; Kato, T; Ohnuma, H; Tominaga, M; Tsuchiya, H; Yamaguchi, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.71) | 18.2507 |
| 2000's | 19 (54.29) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamada, S | 1 |
| Ano, N | 1 |
| Toda, K | 1 |
| Kitaoka, A | 1 |
| Shiono, K | 1 |
| Inoue, G | 1 |
| Atsuda, K | 1 |
| Irie, J | 1 |
| Georgescu, EF | 1 |
| Eriksson, JW | 1 |
| Jansson, PA | 1 |
| Carlberg, B | 1 |
| Hägg, A | 1 |
| Kurland, L | 1 |
| Svensson, MK | 1 |
| Ahlström, H | 1 |
| Ström, C | 1 |
| Lönn, L | 1 |
| Ojbrandt, K | 1 |
| Johansson, L | 1 |
| Lind, L | 1 |
| Yan, WH | 2 |
| Dou, JT | 2 |
| Pan, CY | 2 |
| Chen, K | 1 |
| Wang, XM | 2 |
| Ma, FL | 2 |
| Yang, GQ | 2 |
| Wang, XL | 2 |
| Mu, YM | 2 |
| Lu, JM | 2 |
| Zhou, MS | 1 |
| Schulman, IH | 1 |
| Raij, L | 1 |
| Ozaki, N | 1 |
| Nomura, Y | 1 |
| Sobajima, H | 1 |
| Kondo, K | 1 |
| Oiso, Y | 1 |
| Derosa, G | 2 |
| Maffioli, P | 1 |
| Salvadeo, SA | 2 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Mereu, R | 1 |
| Palumbo, I | 1 |
| Fogari, E | 1 |
| D'Angelo, A | 1 |
| Cicero, AF | 1 |
| Wang, X | 1 |
| Li, F | 1 |
| Jose, PA | 1 |
| Ecelbarger, CM | 1 |
| Watanabe, M | 1 |
| Inukai, K | 1 |
| Sumita, T | 1 |
| Ikebukuro, K | 1 |
| Ito, D | 1 |
| Kurihara, S | 1 |
| Ono, H | 1 |
| Awata, T | 1 |
| Katayama, S | 1 |
| Pavlatou, MG | 1 |
| Mastorakos, G | 1 |
| Margeli, A | 1 |
| Kouskouni, E | 1 |
| Tentolouris, N | 1 |
| Katsilambros, N | 1 |
| Chrousos, GP | 1 |
| Papassotiriou, I | 1 |
| Fogari, R | 1 |
| Zoppi, A | 1 |
| Mugellini, A | 1 |
| Lazzari, P | 1 |
| Santoro, T | 1 |
| Matsumoto, T | 1 |
| Horie, M | 1 |
| Mori, Y | 1 |
| Tanaka, T | 1 |
| Matsuura, K | 1 |
| Yokoyama, J | 1 |
| Utsunomiya, K | 1 |
| Taniguchi, Y | 1 |
| Takahashi, N | 2 |
| Fukui, A | 1 |
| Nagano-Torigoe, Y | 1 |
| Thuc, LC | 1 |
| Teshima, Y | 1 |
| Shinohara, T | 1 |
| Wakisaka, O | 1 |
| Ooie, T | 2 |
| Murozono, Y | 1 |
| Yufu, K | 1 |
| Nakagawa, M | 1 |
| Hara, M | 2 |
| Yoshimatsu, H | 2 |
| Saikawa, T | 2 |
| Müller-Fielitz, H | 1 |
| Landolt, J | 1 |
| Heidbreder, M | 1 |
| Werth, S | 1 |
| Vogt, FM | 1 |
| Jöhren, O | 1 |
| Raasch, W | 1 |
| Sueta, D | 1 |
| Nakamura, T | 1 |
| Dong, YF | 1 |
| Kataoka, K | 1 |
| Koibuchi, N | 1 |
| Yamamoto, E | 1 |
| Toyama, K | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Maeda, A | 1 |
| Tamura, K | 1 |
| Kanaoka, T | 1 |
| Ohsawa, M | 1 |
| Haku, S | 1 |
| Azushima, K | 1 |
| Dejima, T | 1 |
| Wakui, H | 1 |
| Yanagi, M | 1 |
| Okano, Y | 1 |
| Fujikawa, T | 1 |
| Toya, Y | 1 |
| Mizushima, S | 1 |
| Tochikubo, O | 1 |
| Umemura, S | 1 |
| Ando, H | 1 |
| Ushijima, K | 1 |
| Hosohata, K | 1 |
| Saito, T | 1 |
| Fujimura, A | 1 |
| Jesmin, S | 1 |
| Hattori, Y | 1 |
| Sakuma, I | 1 |
| Mowa, CN | 1 |
| Kitabatake, A | 1 |
| Furuhashi, M | 1 |
| Ura, N | 2 |
| Higashiura, K | 2 |
| Murakami, H | 1 |
| Tanaka, M | 1 |
| Moniwa, N | 1 |
| Yoshida, D | 1 |
| Shimamoto, K | 2 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Dell'Oro, R | 1 |
| Trevano, FQ | 1 |
| Bombelli, M | 1 |
| Scopelliti, F | 1 |
| Facchini, A | 1 |
| Mancia, G | 1 |
| Anan, F | 1 |
| Tomiyama, H | 2 |
| Motobe, K | 2 |
| Zaydun, G | 1 |
| Koji, Y | 2 |
| Yambe, M | 2 |
| Arai, T | 1 |
| Kushiro, T | 2 |
| Yamashina, A | 2 |
| Koh, KK | 3 |
| Quon, MJ | 3 |
| Han, SH | 3 |
| Chung, WJ | 3 |
| Lee, Y | 2 |
| Shin, EK | 3 |
| Ahn, JY | 1 |
| Kim, JA | 2 |
| Yamada, J | 1 |
| Yoshida, M | 1 |
| Shiina, K | 1 |
| White, M | 1 |
| Lepage, S | 1 |
| Lavoie, J | 1 |
| De Denus, S | 1 |
| Leblanc, MH | 1 |
| Gossard, D | 1 |
| Whittom, L | 1 |
| Racine, N | 1 |
| Ducharme, A | 1 |
| Dabouz, F | 1 |
| Rouleau, JL | 1 |
| Touyz, R | 1 |
| Iwai, M | 1 |
| Chen, R | 1 |
| Imura, Y | 1 |
| Horiuchi, M | 1 |
| Kinugawa, S | 1 |
| Miyazaki, Y | 1 |
| Sasaki, K | 1 |
| Nakagawa, S | 1 |
| Kanmatsuse, K | 1 |
| Nesbitt, SD | 1 |
| Julius, S | 1 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Yamaguchi, H | 1 |
| Tsuchiya, H | 1 |
| Ohnuma, H | 1 |
| Tominaga, M | 1 |
| Daimon, M | 1 |
| Kato, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for candesartan and Insulin Resistance
| Article | Year |
|---|---|
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fat | 2008 |
Vascular and metabolic effects of candesartan: insights from therapeutic interventions.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol | 2006 |
[Diabetic heart disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
Prehypertension: a possible target for antihypertensive medication.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2000 |
17 trials available for candesartan and Insulin Resistance
| Article | Year |
|---|---|
Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2008 |
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Compo | 2008 |
Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Comp | 2010 |
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compou | 2010 |
Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2011 |
Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2011 |
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ben | 2012 |
Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Area Under Curve; Benzimida | 2013 |
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2003 |
Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Mas | 2004 |
Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2005 |
Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Benzimidazoles; Biph | 2006 |
Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2007 |
Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
Prehypertension: a possible target for antihypertensive medication.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2000 |
15 other studies available for candesartan and Insulin Resistance
| Article | Year |
|---|---|
[Candesartan improves insulin resistance induced by high-fat diet in rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Dietary Fats; | 2008 |
Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzi | 2009 |
Reduction of renal dopamine receptor expression in obese Zucker rats: role of sex and angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2010 |
[Effects of candesartan on expressions of JAK2 and PTP-1B in adipose tissue of high-fat diet-fed rats].
Topics: Adipose Tissue; Animals; Benzimidazoles; Biphenyl Compounds; Insulin Resistance; Janus Kinase 2; Mal | 2010 |
Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation.
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; D | 2011 |
Angiotensin-converting enzyme inhibition and fibrinolytic balance.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2011 |
Candesartan restored cardiac Hsp72 expression and tolerance against reperfusion injury in hereditary insulin-resistant rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Benzimidazoles; | 2011 |
Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARγ target gene regulation.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Co | 2012 |
Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bl | 2012 |
Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2002 |
Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension.
Topics: Adiponectin; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2003 |
TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.
Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphen | 2007 |
Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
[Effects of angiotensin II receptor antagonist on insulin sensitivity and sympathetic activity in spontaneously hypertensive rats].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Carotid Artery, Commo | 2001 |